FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3126661720> ?p ?o ?g. }

• W3126661720 endingPage "266" @default.
• W3126661720 startingPage "259" @default.
• W3126661720 abstract "Botulinum toxin type A (Onabotulinumtoxin A, Incobotulinumtoxin A, Abobotulinumtoxin A) has been successfully used in the treatment of lateral canthal rhytid (crow’s feet) reduction. Prabotulinumtoxin A is a newer medication that has been shown to have efficacy for the treatment of upper limb spasticity and improvement in moderate to severe glabellar lines. This study evaluated the onset of action, maximal effect, duration of action, and side effect profile for Prabotulinumtoxin A compared with Onabotulinumtoxin A in the treatment of crow’s feet. A total of 18 subjects aged 25 to 60 without a previous history of neuromuscular disorders, eyelid surgery, or botulinum toxin type A injections were included. Patients received 3 injections of botulinum toxin in the crow’s feet area on each side. Each side received 4U/.1cc of Prabotulinumtoxin A or Onabotulinumtoxin A at each site for a total of 12U/.3cc. The surgeon was masked to the serotype injected. The subjects had their lateral canthal areas photographed in relaxed and smiling positions preoperatively, daily from postinjection days 1 to 4, and weekly thereafter for a total of 12 weeks. Two masked oculoplastic surgeons were given the preoperative photos and postinjection photos and graded them on a scale of 0 to 3 (0 = no wrinkles, 1 = minimal wrinkles, 2 = moderate wrinkles, 3 = significant wrinkles). All subjects tolerated the injections well with no significant side effects or complications. The average onset of action was 3.47 days (1-14) for Onabotulinumtoxin A and 3.81 (1-14) for Prabotulinumtoxin A. The average time to peak effect was 11.11 days (1-56) for Onabotulinumtoxin A and 9.58 days (2-42) for Prabotulinumtoxin A. The average duration of action with improvement compared with baseline crow’s feet was 11.22 weeks (7-12) for Onabotulinumtoxin A and 11.11 weeks (6-12) for Prabotulinumtoxin A. Treatment of crow’s feet lines with Prabotulinumtoxin A achieves a comparable efficacy and safety profile compared with Onabotulinumtoxin A at a 1:1 dose. Therefore, Prabotulinumtoxin A can be used as another option in the treatment of crow’s feet." @default.
• W3126661720 created "2021-02-15" @default.
• W3126661720 creator A5038043317 @default.
• W3126661720 creator A5069743602 @default.
• W3126661720 creator A5070402328 @default.
• W3126661720 creator A5082301371 @default.
• W3126661720 creator A5088786053 @default.
• W3126661720 date "2021-02-05" @default.
• W3126661720 modified "2023-09-24" @default.
• W3126661720 title "Comparison of Prabotulinumtoxin A to Onabotulinumtoxin A in the Treatment of Lateral Canthal Rhytids: A Side-by-Side, Randomized, Double-Blind Comparison" @default.
• W3126661720 cites W1608538153 @default.
• W3126661720 cites W1970066703 @default.
• W3126661720 cites W2002506016 @default.
• W3126661720 cites W2003090163 @default.
• W3126661720 cites W2017012921 @default.
• W3126661720 cites W2030907440 @default.
• W3126661720 cites W2036461522 @default.
• W3126661720 cites W2048836630 @default.
• W3126661720 cites W2118476715 @default.
• W3126661720 cites W2121811479 @default.
• W3126661720 cites W2305288827 @default.
• W3126661720 cites W2324060972 @default.
• W3126661720 cites W2328002511 @default.
• W3126661720 cites W2340130776 @default.
• W3126661720 cites W2407472901 @default.
• W3126661720 cites W2777145355 @default.
• W3126661720 cites W2922977267 @default.
• W3126661720 cites W2925222137 @default.
• W3126661720 cites W2939183363 @default.
• W3126661720 cites W4226153170 @default.
• W3126661720 cites W4363610867 @default.
• W3126661720 doi "https://doi.org/10.1177/0748806821989882" @default.
• W3126661720 hasPublicationYear "2021" @default.
• W3126661720 type Work @default.
• W3126661720 sameAs 3126661720 @default.
• W3126661720 citedByCount "2" @default.
• W3126661720 countsByYear W31266617202023 @default.
• W3126661720 crossrefType "journal-article" @default.
• W3126661720 hasAuthorship W3126661720A5038043317 @default.
• W3126661720 hasAuthorship W3126661720A5069743602 @default.
• W3126661720 hasAuthorship W3126661720A5070402328 @default.
• W3126661720 hasAuthorship W3126661720A5082301371 @default.
• W3126661720 hasAuthorship W3126661720A5088786053 @default.
• W3126661720 hasConcept C141071460 @default.
• W3126661720 hasConcept C2777478456 @default.
• W3126661720 hasConcept C2781302119 @default.
• W3126661720 hasConcept C71924100 @default.
• W3126661720 hasConceptScore W3126661720C141071460 @default.
• W3126661720 hasConceptScore W3126661720C2777478456 @default.
• W3126661720 hasConceptScore W3126661720C2781302119 @default.
• W3126661720 hasConceptScore W3126661720C71924100 @default.
• W3126661720 hasFunder F4320314346 @default.
• W3126661720 hasIssue "4" @default.
• W3126661720 hasLocation W31266617201 @default.
• W3126661720 hasOpenAccess W3126661720 @default.
• W3126661720 hasPrimaryLocation W31266617201 @default.
• W3126661720 hasRelatedWork W2002120878 @default.
• W3126661720 hasRelatedWork W2003938723 @default.
• W3126661720 hasRelatedWork W2047967234 @default.
• W3126661720 hasRelatedWork W2118496982 @default.
• W3126661720 hasRelatedWork W2364998975 @default.
• W3126661720 hasRelatedWork W2369162477 @default.
• W3126661720 hasRelatedWork W2439875401 @default.
• W3126661720 hasRelatedWork W4238867864 @default.
• W3126661720 hasRelatedWork W2519357708 @default.
• W3126661720 hasRelatedWork W2525756941 @default.
• W3126661720 hasVolume "38" @default.
• W3126661720 isParatext "false" @default.
• W3126661720 isRetracted "false" @default.
• W3126661720 magId "3126661720" @default.
• W3126661720 workType "article" @default.